AtezoCab: A Phase II Study of Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Non-Measurable Disease
Latest Information Update: 28 Feb 2025
At a glance
- Drugs Atezolizumab (Primary) ; Cabozantinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms AtezoCab
- 24 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Apr 2025.
- 18 Feb 2023 Trial design, presented at the 2023 Genitourinary Cancers Symposium
- 11 Mar 2022 Status changed from not yet recruiting to recruiting.